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Western blot analysis. Neither hypoxic pregnancy nor MitoQ treatment affected fetal growth. Hypoxia
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as the UPR, as evidenced by glucose-regulated protein 78 and activating transcription factor (ATF) 4
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London, UK.The placenta is the main interface between the mother and
fetus, and it regulates intrauterine development by supplying
nutrients and oxygen required for fetal growth. There is now
clear evidence that the placenta can sense and respond to
supply signals arising from the mother and demand signals
from the fetus. The organ can adapt morphologically and
functionally to these signals (eg, by altering placental and
fetal blood flow, fetal nutrient supply, and secretion of
signaling molecules, including hormones).1 To date, most of
the research effort on placental adaptation to adverse preg-
nancy has focused on maternal nutritional challenges or
maternal glucocorticoid overexposure and their effects onstigative Pathology. Published by Elsevier Inc.
Y license (http://creativecommons.org/licenses/by/4.0).
Placenta Adaptation to Hypoxia and MitoQplacental structure and function.2,3 Chronic fetal hypoxia is
one of the most common consequences of complicated
pregnancy, and it is associated with a variety of maternal,
placental, and fetal conditions, including pregnancy at high
altitude, gestational diabetes, preeclampsia, and placental
insufficiency.4,5 Despite this, the effect of hypoxia on the
placenta remains relatively unexplored. Decrements in fetal
growth have been observed in rodents exposed to hypoxia
during mid to late pregnancy.6e8 Of interest, compared with
late-onset hypoxic pregnancy that restricts fetal growth,8e10
hypoxia exposure earlier in pregnancy does not necessarily
reduce fetal or birth weight.11,12 This suggests that there are
adaptations in maternofetal resource allocation during early-
onset hypoxia that help to maintain fetal growth and
appropriate development. In relation to the effects of hyp-
oxic pregnancy on placental morphology, the available data
from studies in rodents are variable. Increases, decreases, or
no difference in placental weights; the surface area and
volumes of the maternal and/or fetal compartments; barrier
thickness; and transfer of glucose and amino acids and their
transporters have been reported.7,13e17 This variability is
most likely attributable to differences in the duration,
severity, and mode of induction, and whether exposure to
hypoxia is accompanied by reductions in maternal food
intake during the challenge.9,12,18,19
Placental oxidative stress is implicated in the patho-
physiology of several complications of human pregnancy,
including preeclampsia,20,21 high-altitude pregnancy,22,23
and cases of intrauterine growth restriction.24 Closely
associated to oxidative stress is disruption of endoplasmic
reticulum (ER) function. The ER is a site of integration of
various stress responses, including hypoxia, mediated
principally through the unfolded protein response (UPR),
which aims to restore normal ER function.25e27 The UPR
comprises three highly conserved parallel signaling
branches: protein kinase RNAelike ER kinase (PERK),
inositol-requiring enzyme, and activating transcription fac-
tor (ATF) 6a. Activation of these pathways has been
reported in placentas from human intrauterine growth
restriction infants with or without preeclampsia28e30 and, to
a lesser extent, in healthy pregnancies at high altitude.23
Recently, the potential use of antioxidant therapies to
protect the placenta and fetus against oxidative stress in
complications of pregnancy and birth has attracted much
attention. We developed a rodent animal model of hypoxic
pregnancy that minimizes effects on maternal food intake,
thereby helping to isolate the effects of hypoxia on the
placenta and offspring.11,31 Using this model, we have shown
that early-onset hypoxia from days 6 to 20 of gestation in-
creases placental size and induces placental oxidative stress
and that maternal treatment with the antioxidant vitamin C is
protective.11,31,32 Although these data provide proof of
principle that maternal antioxidant therapy may confer pro-
tection to the placenta and offspring in hypoxic pregnancy, in
these studies, only high doses of vitamin C were effective. In
addition, clinical trials have reported that maternal treatmentThe American Journal of Pathology - ajp.amjpathol.orgwith vitamin C in human pregnancy complicated by pre-
eclampsia did not prove protective to the mother or baby.33,34
Therefore, there is increasing interest in alternative maternal
antioxidant therapies to protect the placenta and offspring in
complicated pregnancy, with greater translational capacity to
the human clinical situation.
Mitochondria-targeted antioxidants might offer a plausible
alternative, becausemost endogenous reactive oxygen species
are generated within mitochondria.35 The most extensively
studied compound of this class is the mitochondria-targeted
ubiquinone derivative MitoQ, which can pass easily through
all biological membranes and accumulate several hundredfold
within mitochondria, thereby enhancing protection from
oxidative damage.36,37 The use of MitoQ in vivo in several
different rodent models of human pathology has shown that
MitoQ can protect against oxidative damage in adult off-
spring.38e45 Furthermore, long-term oral administration is
safe, and unlike other conventional antioxidants, MitoQ does
not demonstrate pro-oxidant activity at high doses in vivo.46,47
An oral preparation of MitoQ has already safely undergone
phase 1 and 2 human clinical trials. A study demonstrated that
MitoQ can be safely administered for 1 year and is well
tolerated by patients.48 To date, only one study has investi-
gated the antioxidant benefits of MitoQ in pregnancy,
reporting that treatment of the pregnant rat with nanoparticle-
bound MitoQ during hypoxic pregnancy could protect fetal
brain development.49 Therefore, the aim of this study was to
investigate the effects of hypoxic pregnancy, with andwithout
maternal treatment with MitoQ, on placental morphologic
capacity for substrate transport and to determine whether
UPR-sensing mechanisms were affected.
Materials and Methods
Experimental Design
All procedures described were approved by the Ethical Re-
view Committee of the University of Cambridge (Cambridge,
UK) and were in accordance with UK Animals (Scientific
Procedures) Act 1986. Power calculations derived from pre-
viously published data using a similar experimental
design11,31,50 were used to determine the minimum numbers
required for statistically valid results, taking into account sex
of the offspring and variations in litter size. Virgin Wistar rats
(Charles River, Margate, UK; 10 to 12 weeks of age) were
mated with male Wistar rats (minimum, 12 weeks of age)
overnight. Pregnancy was confirmed by the presence of a
copulatory plug (day 0, term approximately 22 days). Preg-
nant dams were then housed individually (21C, 60% hu-
midity, 12:12-hour light-dark cycle) with free access to food
(Special Diet Services, Witham, UK) and water. Maternal
weight and food andwater consumption weremonitored daily
throughout gestation. On day 6 of pregnancy, rats were
randomly assigned to either normoxic (21% O2) or hypoxic
(13% to 14% O2) conditions. Two additional normoxic and
hypoxic groups were examined and were given the2705
Nuzzo et almitochondria-targeted antioxidant MitoQ (500 mmol/L in
maternal drinking water), which was prepared fresh daily.
Pregnant dams subjected to hypoxia were placed inside a
chamber, which combined a polyvinyl chloride isolator with a
nitrogen generator, as previously described.31,32,51 The
experimental design, therefore, consisted of four groups:
normoxia (N; n Z 16 litters), hypoxia (H; n Z 16 litters),
hypoxia with MitoQ (HM; nZ 18 litters), and normoxia with
MitoQ supplementation (NM; n Z 16 litters). The dose of
MitoQwas derived from previous animal studies39,46,47,52 and
corresponds to an oral dose of approximately 0.05 mg/day per
gram in rats.38
Tissue Collection
On day 20 of gestation, all dams underwent euthanasia by
carbon dioxide inhalation and cervical dislocation. A maternal
blood sample for measurement of hematocrit was taken by
cardiac puncture. The pregnant uterus was exposed via a
midline incision, and the pups were euthanized via spinal
transection. Maternal blood was centrifuged for determination
of hematocrit. All fetuses and their associated placentas were
weighed. To control forwithin-litter variation, one placentawas
randomly selected and processed for stereology. Another two
placentas from each litter were collected and immediately
frozen in liquid nitrogen forMitoQ uptake and protein isolation
analyses, respectively. Therefore, only one placenta per litter
was used for each outcome measure. Only placentas frommale
pups were collected, to control for sex variation.
MitoQ Uptake
The uptake of MitoQ was assessed in the placenta, maternal
liver, and fetal liver. MitoQ was measured using a liquid
chromatographyetandemmass spectrometry assay.46 Frozen
tissues were homogenized in tris buffer (pH 7.0), extracted
with acetonitrile (Sigma-Aldrich, Gillingham, UK), and dried
overnight under a vacuum. The extracts were reconstituted,
and the MitoQ content was measured using mass spectrom-
etry. Data were analyzed using MassLynx MS software
version 4.1 (Waters, Elstree, UK) and expressed relative to a
deuterated internal standard. Control samples were spiked
with known amounts ofMitoQ from 1 to 500 pmol to generate
a standard curve; the assay could detect as low as 0.1 pmol
MitoQ/100 mg of tissue.
Placental Histology and Stereology
At post-mortem, the placentas randomly selected for stere-
ology were transversally cut into two halves. One half was
immersion fixed in 4% paraformaldehyde, embedded in
paraffin wax, and then completely divided into sections (7
mm thick) perpendicular to the chorionic plate (Leica RM
2235 microtome; Leica Microsystems, Wetzlar, Germany).
Systematic random sampling was used to select, without
bias, 10 sections for analysis.53 Hematoxylin and eosin2706staining of these sections was used to visualize the gross
structure of the rat placenta. Immunohistochemistry was
performed on sections near the placental midline for
markers of mitochondrial stress [glucose-regulated protein
75 (GRP75) and tumorous imaginal disc 1 (TID-1)] and to
localize ATF4 and glucose-regulated protein 78 (GRP78).
The other half of the placenta was fixed with 4% glutaral-
dehyde and embedded in Spurr epoxy resin (Taab, Alder-
maston, UK). A section (1 mm thick) was cut near to the
placental midline and stained with toluidine blue to visu-
alize the structure of the labyrinthine zone.54
The Computer Assisted Stereology Toolbox 2.0 system
from Olympus (Ballerup, Denmark), fitted with a motorized
specimen stage, was used to perform all stereological mea-
surements. All quantitative analyses were performed with the
observer (A.M.N.) blinded to the treatment group. To deter-
mine the absolute volume of the placenta, a point grid was
superimposed on vertically orientated hematoxylin and
eosinestained paraffin sections viewed using a 1.25 objec-
tive lens. Points falling on the sample were counted, and the
Cavalieri principle was applied to reach a volume estimate55:
V(obj) Z t  S a Z t  a(p)  S P, where V(obj) is the
estimated placental volume, t is the total thickness of the
placenta (total number of sections multiplied by section
thickness), a(p) is the area associated with each point, and S P
is the sum of points on sections. At 10 magnification,
meander sampling and point counting were used to estimate
compartment densities of the three placental zones: labyrin-
thine zone (LZ), junctional zone (JZ), and decidua basalis:
Vv(struct,ref) Z P(struct)/P(total), where Vv(struct,ref) is the
volume fraction of a compartment (eg, LZ) within a reference
space (eg, placenta), P(struct) is the number of points falling
on the compartment, and P(total) is the total number of points
falling on the reference space (including the component). The
volume densities obtained were converted to absolute quan-
tities by multiplying by total placental volume.55,56
Resin sections were used to resolve the labyrinth structure
in detail. A 100 objective lens was used, and fields of view
within the LZ were selected by meander sampling to deter-
mine volume densities, surface densities, and interhaemal
membrane thickness. Volume densities of the maternal blood
space and fetal capillaries were obtained using a point grid.54
Volume densities were converted to absolute component
volumes by multiplying by the volume of the LZ. Vascular
surface densities for the maternal blood space and fetal cap-
illaries were obtained using a grid formed of cycloid arcs
placed over each field of view, and intercepts between
maternal blood space boundary and fetal capillary boundary
were counted. The following equation was used to determine
surface areas: S(struct) Z [2  S I(struct)/I(p)  S
P(ref)]  V(ref), where S I(struct) is the total number of in-
tersections of the cycloid arcs with the structure, V(ref) is the
reference volume, S P(ref) is the total number of points that
hit the reference space, and I(p) is the length of the test line
associated with each point in the grid.57 All surface area
densities were converted to absolute surface areas byajp.amjpathol.org - The American Journal of Pathology
Table 1 Maternal Biometric Data
Variable N H HM NM
Hematocrit (%) 34.7  1.9 40.9  1.5* 39.9  1.2* 37.9  0.6
BW (g) 410.2  7.2 395.6  8.6 387.4  10.4 391.4  8.7
CRL (mm) 190.7  2.0 187.2  3.0 199.6  6.1 184.5  4.1
HD (mm) 22.8  0.5 22.7  0.5 22.5  0.3 23.2  0.3
BMI (kg/m2) 11.3  0.3 11.4  0.5 10.0  0.6 11.6  0.5
HD/BW ratio 0.056  0.001 0.058  0.002 0.059  0.002 0.059  0.002
Hematocrit, BW, CRL, HD, BMI, and HD/BW ratio from N, H, HM, and NM dams at day 20 of gestation. Values are means  SEM.
*Significant main effect of hypoxia on hematocrit (P < 0.05, general linear model test). Number of dams for hematocrit: NZ 16; HZ 16; HMZ 18; and
NM Z 16. Number of dams for remaining variables: N Z 10; H Z 10; HM Z 11; and NM Z 11.
BMI, body mass index; BW, body weight; CRL, crown-rump length; H, hypoxic; HD, head diameter; HM, hypoxic þ MitoQ; N, normoxic; NM, normoxic þ
MitoQ.
Placenta Adaptation to Hypoxia and MitoQmultiplying by the volume of LZ. Thickness of the inter-
haemal membrane of the LZ was obtained with a line grid to
establish random start points formeasuring distances between
fetal capillaries and the closest maternal blood space by the
method of orthogonal intercepts.58 Intercept lengths were
multiplied by the factor (8/3)p to correct for plane of
sectioning,59 and the harmonic mean thickness of the mem-
brane was calculated as the reciprocal of the mean of the re-
ciprocals of the corrected intercept distances. The theoretical
diffusion capacity for the interhaemal membrane was calcu-
lated using the following equation: DvmZ K  (mean sur-
face area/mean thickness), where Dvm is the diffusing
capacity across the LZ membrane, K is the Krogh diffusion
coefficient for oxygen (17.3 108 cm2/minute kPa),60mean
surface area is the mean of fetal and maternal surface areas of
the interhaemal membrane, and mean thickness is the har-
monic mean thickness of the interhaemal membrane. The
specific diffusion capacity is an estimate of the diffusing ca-
pacity for oxygen in terms of fetal requirements, obtained by
expressing Dvm per mg of fetal weight.
Immunohistochemistry
Sections near the placental midline were dewaxed and then
rehydrated in water for 10 minutes, incubated with 3% H2O2
for 15minutes, andwashed in tapwater before antigen retrieval
was performed (tris-EDTA buffer, pH 9.0; Sigma-Aldrich).Table 2 Fetal Biometric Data
Variable N H
BW (g) 3.63  0.05 3.41  0.
PW (g) 0.55  0.01 0.62  0.
BW/PW ratio 6.69  0.15 5.77  0.
CRL (mm) 33.19  0.30 32.23  0.
HD (mm) 7.73  0.07 7.72  0.
BMI (kg/m2) 3.33  0.04 3.38  0.
HD/BW ratio 2.14  0.03 2.25  0.
BW, PW, placental efficiency (BW/PW ratio), CRL, HD, BMI, and HD/BW ratio from
Values are means  SEM.
*Significant main effect of hypoxia on placental weight (P < 0.05, mixed linea
NM Z 65. Number of fetuses for remaining variables: N Z 59; H Z 59; HM Z
BMI, body mass index; BW, body weight; CRL, crown-rump length; H, hypoxic;
MitoQ; PW, placental weight.
The American Journal of Pathology - ajp.amjpathol.orgSections were washed with tris-buffered saline (TBS) with
1% Triton-X and 1% Tween-20 (all Sigma-Aldrich) for 30
minutes and then specific binding was blocked with 5% bovine
serum albumin in TBS (Sigma-Aldrich) for 1 hour. Sections
were then incubated overnight at 4C with the following pri-
mary antibodies: UPR-related proteins anti-GRP78 (1:1000;
Transduction Laboratories, BD Biosciences, Oxford, UK) and
anti-ATF4 (1:250; Santa Cruz Biotechnology, Wembley, UK).
They were also incubated with markers of the mitochondrial
matrix: antieTID-1 (1:100;GeneTex,Wembley,UK) and anti-
GRP75 (1:100; Abcam, Cambridge, UK). Negative control
samples were obtained by omitting the primary antibody. The
following day, sections were washed 15 minutes in TBS with
1% Triton-X and 1% Tween-20, incubated for 1 hour with
secondary antibody (Vector Laboratories, Peterborough, UK),
and then washed for 15 minutes in TBS with 1% Triton-X and
1%Tween-20. Sections were incubated for 45minutes in avidin/
biotin (Vector Laboratories) in TBS, then washed in TBS for 10
minutes. Staining was visualized with 3,30-diaminobenzidine
tetrahydrochloride/hydrogen peroxide (Sigma-Aldrich) for 2
minutes. Slides were rinsed with water, dehydrated, and then
coverslipped with DPX (Sigma-Aldrich).
OD
The OD of GRP75 and TID-1 immunostaining was
measured in the LZ and JZ using a calibrated OD step tabletHM NM
03 3.72  0.06 3.39  0.04
01* 0.60  0.01* 0.54  0.01
15 6.44  0.18 6.49  0.15
30 33.12  0.24 32.35  0.31
06 7.78  0.07 7.60  0.06
08 3.43  0.04 3.32  0.05
03 2.09  0.04 2.25  0.03
male fetuses only from N, H, HM, and NM pregnancy at day 20 of gestation.
r model test). Number of fetuses for BW: N Z 74; HZ 86; HM Z 84; and
62; and NM Z 54.
HD, head diameter; HM, hypoxic þ MitoQ; N, normoxic; NM, normoxic þ
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Figure 1 Effects of maternal hypoxia with or without MitoQ treatment on
maternal parameters during days 6 to 20 of gestation. A: Maternal food
intake expressed relative to body weight. B: Maternal water intake expressed
relative to body weight. C: Maternal body weight in normoxic (N), hypoxic
(H), hypoxic þ MitoQ (HM), and normoxic þ MitoQ (NM) pregnancies. Data
are expressed as means  SEM. *P < 0.05 versus N; yP < 0.05 versus H;
zP < 0.05 versus NM (general linear model repeated-measures test).
Nuzzo et al(ImageJ software version 1.80; NIH, Bethesda, MD; http://
imagej.nih.gov/ij). For each placenta, 10 fields within each
region (LZ and JZ) were examined.
Western Blot Analysis
Whole placental tissue was homogenized in cell lysis buffer
and amini protease inhibitor cocktail (RocheDiagnostics, East
Sussex, UK). The protein concentration of the lysates was
measured by a bicinchoninic acid protein assay (Sigma-
Aldrich). The samples were mixed with SDS-PAGE gel
loading buffer (50 mmol/L tris-HCl, pH 6.8, 100 mmol/L
dithiothreitol, 2% SDS, 10% glycerol, and bromophenol blue)
and boiled for 5 minutes. Equivalent amounts of protein (1 mg/
mL) were resolved by SDS-PAGE, blotted onto nitrocellulose
membranes (0.2 mm thick), and probed overnight at 4C with
the following primary antibodies: anti-GRP78 (Transduction
Laboratories, BD Biosciences), anti-AKT (Cell Signaling
Technology, Hitchin, UK), antieATF-4 (Santa Cruz
Biotechnology), antiephosphorylated AKT (Thr308) (Santa
Cruz Biotechnology), antie4-hydroxynonenal (Merck Milli-
pore, Watford, UK), and antie70-kDa heat shock protein
(Enzo Life Sciences, Exeter, UK). Antieb-actin (Sigma-
Aldrich) was used to normalize protein levels. Some mem-
branes were reprobed with antibodies of different molecular
weight or those that were raised in a different species. The
membranes were analyzed by enhanced chemiluminescence
(Amersham Biosciences, Little Chalfont, UK) using Kodak
X-OMATandrogen receptorfilm (Sigma-Aldrich). Filmswere
scanned using a flat-bed scanner (Canon 8000F; Reigate,
Surrey, UK), and the intensity of the bands was determined
from two or three different exposures (within the linear
detection range) using ImageJ analysis software.61
Statistical Analysis
All data are expressed as means  SEM. Maternal pregnancy
variables and biometry, placenta stereology, and molecular
analyses were compared statistically using a general linear
model test with repeated measures when appropriate (SPSS
V24.0; IBM, Armonk, NY). Fetal biometry was assessed
using the linear mixed models (SPSS V24.0), which nests
offspring data within a maternal identifier, thereby accounting
for the shared maternal environment.62 For all comparisons,
significance was accepted when P < 0.05.
Results
Maternal and Fetal Biometry
Maternal hypoxia induced a significant increase in maternal
hematocrit (P Z 0.002) (Table 1) and placental weight
(P Z 0.002) (Table 2). Body weight and other fetal bio-
metric variables were unaltered by hypoxic pregnancy or
MitoQ treatment (Table 2). Similarly, litter size (N,
15.3  0.8; H, 16.8  0.6; HM, 14.5  1.0; NM,270814.00  1.2) and sex ratio (percentage of males: N,
49.5%  4.0%; H, 50.6%  3.4%; HM, 54.5%  4.9%;
NM, 46.1%  3.8%) were unchanged. Maternal exposure to
hypoxia did not alter maternal weight gain with advancing
gestation nor reduce maternal food or water intake until
days 18 of gestation (Figure 1). Between days 18 and 19 of
gestation, all pregnant dams showed a reduction in maternal
food intake relative to days 7 to 17 of gestation (all
P < 0.05), which was more pronounced in hypoxic relative
to normoxic pregnancy (P Z 0.002) (Figure 1B). Maternal
treatment with MitoQ in normoxic and hypoxic pregnancy
led to a transient, but significant, fall of similar magnitude in
maternal food and water intake (Figure 1, A and B) and
maternal body weight (Figure 1C) soon after the onset of
administration on day 6 of gestation (all P  0.001). Shortly
afterward, maternal body weight gain and food and water
intake recovered toward control values with advancing
gestation in normoxic and hypoxic pregnancy treated with
MitoQ. However, in MitoQ-treated pregnancies, water,
rather than food, intake appeared more affected (Figure 1).ajp.amjpathol.org - The American Journal of Pathology
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Figure 3 Effects of maternal hypoxia with or without maternal MitoQ
treatment on the volume and surface area of fetal capillaries (FCs) and
maternal blood spaces (MBSs) at day 20 of gestation. AeD: FC absolute
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Figure 2 Effects of maternal hypoxia with or without MitoQ treatment on
placental volumes at day 20 of gestation. A and B: Total placental volume (A)
and compartmental volume (B) in normoxic (N), hypoxic (H), hypoxicþMitoQ
(HM), and normoxic þ MitoQ (NM) pregnancies. C: A representative hema-
toxylin and eosinestained paraffin section of the placenta is shown for each
group. Data are expressed as means  SEM. *P < 0.05 versus N; zP < 0.05
versus NM (general linear model test). Scale bar Z 1 mm (C). DB, decidua
basalis; JZ, junctional zone; LZ, labyrinthine zone.
Placenta Adaptation to Hypoxia and MitoQMitoQ Uptake
MitoQ uptake (pmol MitoQ/g wet weight of tissue),
measured by a liquid chromatographyetandem mass spec-
trometry assay, was expressed relative to untreated nor-
moxic and hypoxic dams and their fetuses. By day 20 of
gestation, MitoQ accumulation was greatest in the maternal
liver [HM, 173  37 pmol/g (nZ 9); NM, 192  40 pmol/g
(nZ 10)], followed by the placenta [HM, 132  28 pmol/g
(n Z 10); NM, 78  24 pmol/g (n Z 11)] and then fetal
liver [HM, 8.5  2.2 pmol/g (n Z 10); NM, 11.4  3.7
pmol/g (n Z 10)].volume and surface area (A and B, respectively) and MBS absolute volume
and surface area (C and D, respectively) in normoxic (N), hypoxic (H),
hypoxic þ MitoQ (HM), and normoxic þ MitoQ (NM) pregnancies. E: A
representative toluidine blueestained resin section of the labyrinthine
zone is shown from one placenta per group. Data are expressed as
means  SEM. *P < 0.05 versus N; zP < 0.05 versus NM (general linear
model test). Scale bars Z 50 mm (E). T, trophoblast.Placental Morphology
At day 20 of gestation, the absolute volume of hypoxic pla-
centas was greater than that of normoxic placentasThe American Journal of Pathology - ajp.amjpathol.org(PZ 0.014) (Figure 2, A and C). The absolute volumes of the
labyrinthine zone, junctional zone, and decidua were pro-
portionally increased in hypoxic pregnancies (LZ,
P Z 0.046; JZ, P Z 0.034; decidua basalis, P Z 0.015)
(Figure 2B). Although hypoxia did not affect total fetal
capillary volume in the labyrinthine zone (Figure 3A), total
fetal capillary surface area was significantly increased
compared with normoxic placentas (PZ 0.005) (Figure 3B);
maternal blood space volume and surface area were un-
changed (Figure 3D). Placental efficiency, expressed as the
ratio of fetal body weight/fetal capillary area and maternal
blood space area, was significantly reduced in placentas from
hypoxic pregnancy (P Z 0.021) (Figure 4). Interhaemal
membrane thickness and theoretical and specific diffusion
capacity were unaltered in hypoxic pregnancy (Figure 5).
In hypoxic pregnancy treated with MitoQ, absolute
placenta volume was increased relative to normoxic preg-
nancy (P Z 0.039) (Figure 2, A and C). Furthermore, the
absolute volume of the decidua basalis was increased
(P Z 0.010) (Figure 2B). MitoQ treatment in hypoxic
pregnancy did not alter absolute fetal capillary volume
(Figure 3, A and E); however, fetal capillary surface area2709
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Figure 4 Effects of maternal hypoxia with or without maternal MitoQ
treatment on placental efficiency at day 20 of gestation. Fetal body weight
(FW) expressed relative to fetal capillary (FC) and maternal blood space
(MBS) areas in normoxic (N), hypoxic (H), hypoxic þ MitoQ (HM), and
normoxic þ MitoQ (NM) pregnancies. Data are expressed as means  SEM.
*P < 0.05 versus N (general linear model test).
Nuzzo et alwas increased relative to placentas from normoxic preg-
nancy (PZ 0.049) (Figure 3, B and E). In addition, MitoQ
treatment in hypoxic pregnancy increased both maternal
blood space volume (P Z 0.033) (Figure 3, C and E) and
surface area (P Z 0.041) (Figure 3, D and E). Placental
efficiency (Figure 4), the thicknesses of the interhaemal
membrane, and the theoretical and specific diffusion ca-
pacities remained unaltered (Figure 5). In normoxic preg-
nancy, MitoQ administration did not affect placental
morphology (Figures 2, 3, 4, and 5).A
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Figure 5 Effects of maternal hypoxia with or without maternal MitoQ
treatment on barrier thickness, theoretical diffusion capacity (TDC), and
specific diffusion capacity (SDC) of the placental interhaemal membrane at
day 20 of gestation. Barrier thickness (A), TDC (B), and SDC (C) in normoxic
(N), hypoxic (H), hypoxic þ MitoQ (HM), and normoxic þ MitoQ (NM)
pregnancies. Data are expressed as means  SEM (AeC).Placental Unfolded Protein Response, Cell
Proliferation, and Oxidative and Mitochondrial Stress
Signaling Pathways
In hypoxic pregnancy, GRP78 (PZ 0.001) (Figure 6A) and
ATF4 abundance (P < 0.001) (Figure 6B) were significantly
increased in the placenta relative to normoxic pregnancy. In
hypoxic pregnancy treated with MitoQ, GRP78 remained
elevated relative to normoxic pregnancies (P Z 0.032)
(Figure 6A); however, ATF4 expression was restored to
normoxic levels (PZ 0.130) (Figure 6B). Therewas no effect
of MitoQ supplementation in normoxic pregnancy on GRP78
or ATF4 (Figure 6). Across all treatment groups, GRP78
expression was localized to the JZ, whereas AFT4 staining
was seen in both the LZ and JZ (Figure 6). Total AKT
(Figure 7A), phosphorylated AKT (Thr308) (Figure 7B), 70-
kDa heat shock protein (Figure 7C), and 4-hydroxynonenal
(Figure 7D) were unaltered by hypoxia and/or MitoQ.
Both GRP75 and TID-1, which localize to the mitochon-
drial matrix, were ubiquitously expressed throughout the
placenta. The staining intensity (OD) of GRP75 was
increased in both the LZ (Figure 8A) and JZ [N, 0.23 0.1; H,
0.29  0.02; HM, 0.24  0.01; NM, 0.21  0.01 (both
P < 0.05)] in hypoxic placentas, but restored with MitoQ
treatment. A similar trend was observed with TID-1, which
was increased in the LZ in hypoxic pregnancy only
(Figure 8B). No changes in TID-1 staining were observed in
the JZ for OD (N, 0.18  0.1; H, 0.20  0.01; HM,
0.16 0.02; NM, 0.16 0.01). There was no effect ofMitoQ2710supplementation in normoxic pregnancy on GRP75 or TID-1
staining (Figure 8).Discussion
The data show that early-onset hypoxic pregnancy modifies
the placental morphologic phenotype that offsets increased
signaling in placental UPRpathways tomaintain fetal growth.
Hypoxic pregnancy increased placental volume and the fetal
capillary surface area within the labyrinthine transport zone
and induced the UPR and mitochondrial stress, as evidenced
by up-regulation of GRP78, ATF4, GRP75, and TID-1 pro-
tein abundance. Maternal treatment with the mitochondria-
targeted antioxidant MitoQ in hypoxic pregnancy further
increased placental maternal blood space surface area and
volume and restored activation of the ATF4 pathway,
normalizing UPR and mitochondrial stress signaling mecha-
nisms toward levels observed in normoxic pregnancy.
Effects of Hypoxic Pregnancy on Placental Morphology
and Fetal Biometry
In the rat, the placenta is fully developed by approximately day
14 of gestation.63 This means that in the present model ofajp.amjpathol.org - The American Journal of Pathology
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Figure 6 Effects of maternal hypoxia with or without maternal MitoQ treatment on endoplasmic reticulum stress signaling pathway at day 20 of gestation.
Representative Western blots and mean densitometry for glucose-regulated protein 78 (GRP78; A) and activating transcription factor 4 (ATF4; B) in normoxic
(N), hypoxic (H), hypoxic þ MitoQ (HM), and normoxic þ MitoQ (NM) placentas. After normalization to b-actin, the mean density of the samples was
expressed relative to normoxic placentas, assigned an arbitrary value of 1. Representative sections show the localization of GRP78 and ATF4 in the labyrinthine
and junctional zones of the placenta. Data are expressed as means  SEM. *P < 0.05 versus N; zP < 0.05 versus NM; xP < 0.05 versus HM (general linear model
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Placenta Adaptation to Hypoxia and MitoQhypoxic pregnancy, the placenta developed under hypoxic
conditions. In this study, it was demonstrated that the placenta
adapts morphologically to early-onset hypoxia by increasing
placental volume. Volumes of the decidua basalis, junctional
zone, and labyrinthine zone were proportionally larger in
hypoxic pregnancy, in association with expansion of the fetal
capillary surface area within the labyrinthine zone. No
changes were observed in the volume or surface area of
maternal blood spaces or thickness of the placental inter-
haemel membrane. Similar beneficial changes in placental
vascularization have been observed in the placentas of mice
(13% oxygen, days 1 to 1915 and days 14 to 1913) and rats
(11%oxygen, days 7 to 1416,17) exposed to hypoxia from early
tomidpregnancy and in human pregnancy at high altitude.56,64
The increase in fetal capillary blood surface area may repre-
sent a compensatory adaptation to increase or maintain
placental transport capacity, thereby protecting fetal growth.
By contrast, hypoxic pregnancy treated with MitoQ not only
increased placental volume and fetal capillary surface area in
the labyrinthine zone but also expanded maternal blood
spaces. The thickness of the placental interhaemel membrane
was not altered. The ability of MitoQ to enhance maternal
blood perfusion of the hypoxic placenta may represent an
additional protective mechanism to enhance the delivery of
substrates for fetal growth. Accordingly, data in the presentThe American Journal of Pathology - ajp.amjpathol.orgstudy also show that maternal treatment with MitoQ in hyp-
oxic pregnancy also restored the impaired placental efficiency
to control levels. Nitric oxide (NO) is important for the
maintenance of umbilical blood flow; an increase in NO
bioavailability can promote umbilical vasodilatation. The
antioxidants melatonin and vitamin C can increase umbilical
blood flow via NO-dependent mechanisms.65MitoQ has been
shown to improve endothelial function in aged mice66 and
stroke-prone spontaneously hypertensive rats,39 by enhancing
NO bioavailability. Substantial evidence suggests that
endothelium-derived NO is a major mediator of angiogen-
esis.67 Taken together, these lines of evidence suggest that the
enhanced volume of maternal blood spaces in the placenta of
MitoQ-treated hypoxic pregnancies may be secondary to an
increase in NO availability and NO-induced angiogenesis of
uterine vessels that supply the labyrinthine zone.
Effects of Hypoxic Pregnancy on Unfolded Protein
Response and Cell Proliferation Signaling Mechanisms
There are three arms of the UPR signaling pathway, including
PERK, ATF6, and inositol-requiring enzyme. Our previous
publications have demonstrated only activation of the
PERKeeukaryotic initiation factor 2aeATF4 arm of the
pathway in mice housed under hypoxic conditions,15 in2711
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Figure 7 Effects of maternal hypoxia with or
without maternal MitoQ treatment on oxidative
stress and lipid-peroxidation markers at day 20 of
gestation. Representative Western blot analysis
and mean densitometry for AKT (A), AKT phos-
phorylation at Thr308 residues (p-AKT Thr308; B),
70-kDa heat shock protein (HSP70; C), and 4-
hydroxynonenal (4-HNE; D) in normoxic (N),
hypoxic (H), hypoxic þ MitoQ (HM), and
normoxic þ MitoQ (NM) placentas. After normali-
zation to b-actin, the mean density of the samples
was expressed relative to normoxic placentas,
assigned an arbitrary value of 1. Data are
expressed as means  SEM.
Nuzzo et alhuman placentas from high altitude,23 and in trophoblast cells
exposed to 1% O2.
23 Therefore, the PERK arm of the UPR
signaling pathway was studied. ATF4 expression is a known
readout of the phosphorylation status of eukaryotic initiation
factor 2a. We have previously reported activation of
eukaryotic initiation factor 2a when tissue was collected 30
minutes after placental separation from the uterine wall.68 In
comparison to the process of phosphorylation, which rapidly
switches on and off, the expression of the ATF4 gene and then
translation into proteins take considerably longer and are less
influenced by tissue collection and handling. Therefore,
ATF4 was considered as a biomarker for ER stress in the
present study. GRP78 protein abundance was shown to be
increased in the placenta of hypoxic pregnancy, with or
without MitoQ treatment. In addition, ATF4 protein abun-
dance was significantly elevated in hypoxic pregnancy but
restored to normoxic levels withMitoQ treatment. GRP78, an
ER chaperone protein, plays a crucial role in the regulation of
the ER dynamic equilibrium and guides misfolded proteins
out of the ER and into the cytosol for degradation.69 PERK-
ATF4 is a key UPR signaling mechanism in the adaptive
response of cells to oxidants and increases in response to
cellular stresses.70 Under hypoxic conditions, there is not
only an increase in mitochondrial reactive oxygen species
production but also a disruption of calcium homeostasis in the
mitochondria, cytosol, and ER.71 Loss of calcium from the
ER lumen, which leads to a perturbation in ER homeostasis, is
one of the major triggers of the UPR.72 Therefore, the data
suggest that early-onset hypoxic pregnancy up-regulates
placental GRP78 in an attempt to reestablish ER homeosta-
sis and resolve ER stress. On the other hand, activation of the
PERK-ATF4 pathway may increase oxidative defense2712mechanisms by facilitating antioxidant enzyme expression.73
Indeed, this hypothesis is supported in the present study in
hypoxic pregnancy supplemented by MitoQ. In this instance,
the lack of up-regulation of ATF4 in response to increased
placental GRP78 implies that exogenous MitoQ supple-
mentation renders the activation of placental oxidative de-
fense mechanisms unnecessary. Our data support previous
studies in which GRPs have been shown to be induced by
hypoxic conditions.74e76 Severe hypoxia or anoxia has been
shown to activate ATF4.77,78 Of interest, both GRP78 and
AFT4 protein levels have been shown to be up-regulated in
the placentas of women with either early- or late-onset
preeclampsia.79e81
The AKTemammalian target of rapamycin signaling
pathway plays a crucial role in the regulation of placental
size. AKTemammalian target of rapamycin signaling has
been shown to be up-regulated in pregnancies from obese
women82 and down-regulated in placentas from
growth-restricted pregnancies.28 In relation to hypoxic
pregnancy, studies have shown both up-regulation and
down-regulation of this pathway, in rodent and human
pregnancies.13,15,23 In the present study, placental AKT
and phosphorylated AKT (Thr308) protein expression
remained unchanged, despite an increase in placental
volume in hypoxic pregnancy. This suggests that other
growth regulatory pathways may be involved, such as the
mitogen-activated protein kinase.83
In the current study, there was no evidence of oxidative
stress or lipid peroxidation in hypoxic placentas with or
without MitoQ treatment. However, the immunostaining of
the mitochondrial stress markers GRP75 and TID-1 was
found to be increased in the placentas of hypoxicajp.amjpathol.org - The American Journal of Pathology
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Figure 8 Effects of maternal hypoxia with or without maternal MitoQ treatment on mitochondrial stress at day 20 of gestation. The mean OD of glucose-
regulated protein 75 (GRP75; A) and tumorous imaginal disc 1 (TID-1; B) staining in normoxic (N), hypoxic (H), hypoxic þ MitoQ (HM), and normoxic þ MitoQ
(NM) placentas. Representative sections showing the intensity of GRP75 and TID-1 staining in the labyrinthine zone (LZ) of the placenta. Data are expressed as
means  SEM. *P < 0.05 versus N; zP < 0.05 versus NM; xP < 0.05 versus HM (general linear model test). Scale bar Z 100 mm (A and B).
Placenta Adaptation to Hypoxia and MitoQpregnancies but restored with MitoQ treatment. There is
extensive evidence in the literature of studies, including our
own, for the protection of mitochondrial function in vivo by
MitoQ treatment in other tissues from various animal
models of pathology, including the liver,84 heart,85 kid-
ney,86 and vascular endothelial cells.66 Taken together, our
data, therefore, demonstrate that hypoxia induces a low-
grade ER and mitochondrial stress by activating the
PERKeeukaryotic initiation factor 2aeATF4 pathway;
however, treatment of hypoxic pregnancy with MitoQ was
effective in suppressing their activation.
MitoQ Uptake during Pregnancy
In the current study, MitoQ was administered at a dose of
500 mmol/L in the dam’s drinking water, from day 6 to day
20 of pregnancy. This equated to approximately 0.044 mg
MitoQ/g per day. Liquid chromatographyetandem mass
spectrometry results indicated that MitoQ uptake by the
placenta and maternal liver was considerably greater than
that of the fetal liver. The range of tissue concentrations of
MitoQ in the placenta (approximately 105 pmol/g) and
maternal liver (approximately 180 pmol/g) is comparable to
concentrations that have been demonstrated to protect cells
in culture from oxidative damage.87 Previous studies in
which the same dose was administrated to mice in drinkingThe American Journal of Pathology - ajp.amjpathol.orgwater over several weeks demonstrated a rapid steady-state
distribution of the compound in the heart, liver, kidneys, and
skeletal muscle.36 During pregnancy, MitoQ uptake appears
low in the fetus. This suggests that the potential benefit to
the fetus of MitoQ supplementation at this dose during
complicated pregnancy is via actions directly on the
placenta. These findings are in keeping with the protective
effects of MitoQ on fetal brain development, despite being
bound to nanoparticles that prevented transfer of the anti-
oxidant to the fetus.49
Maternal Hematocrit and Food and Water Intake
Hypoxia-inducible factors orchestrate the classic physio-
logical response to systemic hypoxia that results in
increased erythropoietin levels and an increase in red blood
production.88 MitoQ in hypoxic pregnancy did not prevent
the increase in maternal hematocrit measured in untreated
hypoxic pregnancy, suggesting that supplementation with
MitoQ does not affect maternal oxygen sensing. In the
present study, maternal food and water intake, as well as
maternal weight, were transiently affected by maternal
treatment with MitoQ in both normoxic and hypoxic preg-
nancy. This suggests that the pregnant rats possibly had to
adapt to the taste of MitoQ. However, in human clinical
trials with MitoQ administration, possible taste adversity has2713
Nuzzo et albeen satisfactorily resolved by formulating treatment via a
tablet.48,89Future Directions
There is growing evidence for the importance of addressing
sex differences in the programing of disease by adverse
prenatal conditions. The placentas from male offspring were
studied because males appear more sensitive to altered ox-
ygen and supply because of their higher rate of intrauterine
growth, relative to females.90 In the present study, sex dif-
ferences were controlled, but not addressed. Future studies
should examine the sex-specific effects of hypoxic preg-
nancy, with or without antioxidant treatment, on placenta
phenotype.
Although maternal antioxidant therapy was administered
from the onset of chronic fetal hypoxia, which may limit
translation to the clinic, the data provide proof of principle
that mitochondria-targeted antioxidants may be beneficial in
complicated pregnancy. Clinically, diagnosis of chronic
fetal hypoxia would need to be established before the in-
duction of maternal antioxidant treatment. Studies in chick
embryos have reported that treatment of hypoxic in-
cubations with agents that increase NO bioavailability or
antioxidants, such sildenafil or melatonin, can protect
against cardiovascular dysfunction in the offspring, even
when therapy is started 12 days after the induction of
chronic hypoxia.91,92 The chick embryo may, therefore,
prove a useful model to further assess human translational
mitochondrial-targeted antioxidant therapies in pregnancies
complicated by hypoxia.Conclusions
Early-onset hypoxic pregnancy in rodents induces
morphologic adaptations in the placenta that offset
increased placental UPR signaling, aiming to sustain fetal
growth. Maternal treatment with the mitochondria-targeted
antioxidant MitoQ in hypoxic pregnancy conferred pro-
tection against placental UPR activation and mitochondrial
stress; and it further modified placental morphology by
increasing the maternal blood spaces. The data suggest that
mitochondria-targeted antioxidants may be beneficial in
complicated pregnancies and minimize the detrimental
effects on fetal development of reduced oxygen delivery
via mechanisms protecting against activation of the
placental UPR, thereby enhancing placental perfusion and
efficiency.Acknowledgment
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